Speaker Lecture Titles

Please see below the partial list of confirmed speakers

Last Name

First Name

Country

Title

Ashe Karen USA Tau cleavage by caspase-2 in tauopathies
Attems Johannes UK The overlap between Alzheimer and Lewy body pathologies
Barthélemy Nicolas USA Tau isoforms changes in brain and biofluids: diagnostic perspective and new insights on pathways involved in AD tauopathy
Bateman Randall USA Advances in Alzheimer’s disease prevention trials: DIAN-TU updates and transition to blood test screening
Bezard Erwan France Astonishing impact of patient-derived a-synuclein extracts and stealth recombinant a-synuclein polymorphs calls for careful thinking before developing therapeutics
Bezprozvanny Ilya USA Sigma 1 receptor as potential therapeutic target for AD
Blennow Kaj Sweden Blood biomarkers for Alzheimer’s disease – the promise for screening, diagnostics and therapy monitoring
Blurton Jones Mathew USA Examining the function of AD risk genes in human microglia and chimeric models
Brooks David UK Does inflammation protect or exacerbate AD and PD progression
Buee Luc France Anti-tau immunotherapy: side effects and specificity
Canavan Michelle Ireland Association of Blood Pressure Lowering with Incident Dementia or Cognitive Impairment.
Association of Blood Pressure Lowering with Incident Dementia or Cognitive Impairment
Checler Frédéric France XBP1S-PINK1 functional interplay unravels molecular links between reticular stress and mitophagy
Chiba-Falek Ornit USA Decoding the Genetic Architecture of Late-Onset Alzheimer’s Disease Using Single-Cell Multi-Omics
Cleveland Don USA Generating new neurons in the adult brain: therapeutic reversal of chemically induced Parkinson’s disease by converting astrocytes into nigral neurons
Cuello Claudio A. Canada Arguments for an early Alzheimer’s nano-Lithium therapy
Cummings Jeffrey USA Alzheimer Therapeutics: Potential Pipeline Predictions
De Strooper Bart Belgium The microglia response to amyloid plaques
Diamond Marc USA Functional classification of tau prions and their relationship to tauopathies
Duff Karen USA Mechanisms of vulnerability to tauopathy
Falcon Benjamin UK Linking amyloid structure to neurodegenerative disease
Fändrich Marcus Germany Cryo-EM structure and polymorphism of Abeta amyloid fibrils purified from Alzheimer’s brain tissue
Frenkel Dan Israel Presenilin 1 role in mediating glia cell activity in Alzheimer’s disease
Galvin James USA Designing Dementia Prevention Studies: Using Proxy Biomarkers to Identify At-Risk Individuals
Gerwert Klaus Germany Aβ-Structure as Precise Plasma Biomarker for Symptom-Free Alzheimer’s Disease Stage
Giladi Nir Israel LRRK2-PD Vs. GBA-PD, an evolving story of genetic role in Parkinson’s disease
Goate Alison USA Genetic studies implicate microglial function in Alzheimer’s disease risk
Gold Gabriel Switzerland Making sense of mixed pathology in the oldest-old
Golde Todd USA Non-amyloid plaque associated proteins as key mediators of Alzheimer’s pathology
Growdon John USA PET scans aid in the differential diagnosis of parkinsonian syndromes
Haass Christian Germany Therapeutic Modulation of TREM2 function
Halliday Glenda Australia The role of glia in progressing alpha-synuclein pathologies
Hansson Oskar Sweden Novel fluid and PET imaging markers for neurodegenerative diseases
Hardy John UK Genomic analysis of neurodegenerative disease
Heneka Michael Germany Mutual interactions between immunity and degeneration in Alzheimer’s disease
Herz Joachim USA A Rational Preventive Approach to Reverse ApoE4 AD Risk
Higuchi Makato Japan Multimodal imaging of tau and alpha-synuclein pathologies
Holtzman David USA Role of astrocyte-derived ApoE in tau-mediated neurodegeneration
Hyman Bradley USA Complexity of dissecting dementia progression in AD
Iaedecola Costantino USA Neurovascular bases of neurodegeneration
Isacson Ole USA Neurons, astrocytes and microglia uniquely change their lipid load with a primary pathology in glycolipid and metabolic pathways in Parkinson’s disease.
Iwatsubo Takeshi Japan Preclinical Alzheimer’s Clinical Trials: TRC-PAD and A4 in Japan
Jack Clifford USA The future of imaging and biofluid Alzheimer’s biomarkers
Jeon Beomseok Korea GI synucleinothay as a biomarker in Parkinson’s disease: an update
Krainc Dimitri USA Mechanistic insights into familial and sporadic Parkinson’s disease: therapeutic implications
Kulisevsky Jaime Spain Cognitive Aspects of Huntington’s Disease
Laferla Frank USA MODEL-AD 2021 Overview: Developing the Next Generation of AD Mouse Models
Lazarov Orly USA Molecular and cellular mechanisms underlying memory failure in Alzheimer’s disease
Lee Virginia USA TBA
Lee Seung-Jae Korea Interplay between synucleinopathy propagation and neuroinflammation
Lemere Cynthia USA Novel Global and Cell-Specific Complement C3 Conditional Knockout Mouse Models
Lipton Stuart USA Hidden Networks of Transnitrosylated Proteins Underlie Synaptic Damage in Neurodegenerative Diseases.
Marek Ken USA Novel Biomarkers across the PD continuum – PPMI 2.0
Masliah Eliezer USA Progress Towards Understanding Alzheimer’s Disease and Related dementias in the Context of Aging
Masters Colin Australia Preclinical diagnosis of AD and  preventative therapeutic strategies
McLean Pamela USA Therapeutic strategies to target alpha-synuclein levels in synucleinopathies
Michaelson Daniel M. Israel ApoE4: an emerging therapeutic target of Alzheimer’s disease
Morgan Dave USA Comparison of different methods of inducing tau pathology in mice. Transgenesis, intracranial transduction and systemic tranduction
Morizane Asuka Japan Cell therapy for Parkinson’s disease with induced pluripotent stem cells
Morris John USA Racial differences in molecular biomarkers for Alzheimer disease
Mucke Lennart USA Molecular and Cellular Modulators of Neural Network Dysfunction in Alzheimer’s Disease: From Tau to Microglia
Multhaup Gerhard Canada Metabolism of BACE1-mediated amyloid clearance products
Nielsen Henrietta Sweden The significance of apolipoprotein E levels in relation to neurodegenerative disease in humans
Nordberg Agneta Sweden Correlation between neuroinflammation, tau pathology and synapse activity in neurodegenerative disorders
Okazawa Hitoshi Japan Deciphering and tacking the ultra-early phase pathology of Alzheimer’s disease
Outerio Tiago Germany Glycation: an age-associated process that drives neurodegeneration in synucleinopathies
Petersen Ronald USA Alzheimer’s Diagnosis in the Era of Biomarkers 2021
Poewe Werner Austria DMT in PD – where do we stand?
Polymenidou Magdalini Switzerland Aggregation-dependent and independent mechanisms of toxicity in TDP-43 and FUS proteinopathies
Prado Marco Canada Cell type-specific cholinergic signalling improves plaque pathology and neuroinflammation in humanized knock-in APP mice
Price Julie USA PET methodology considerations for amyloid and tau imaging
Quiroz Yakeel USA TBA
Rabinovici Gil USA Impact of Amyloid PET on Health Outcomes: Update on the IDEAS study
Ranum Laura USA RAN TRANSLATION IN C9ORF72 ALS/FTD AND OTHER REPEAT EXPANSION DISEASES: MOLECULAR INSIGHTS AND THERAPEUTIC OPPORTUNITIES
Rektorova Irena Czech Republic Cognitive impairment in Parkinson’s disease: neural correlates and treatment approaches
Rosa-Neto Pedro Canada Staging Alzheimer’s disease using biomarkers: application for clinical trials
Sabbagh Marwan USA RATIONALE FOR THE MCLENA-1: A PHASE II CLINICAL TRIAL FOR THE ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF  LENALIDOMIDE IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE
Salloway Stephen USA Creating pathways for breakthroughs in Alzheimer’s disease
Schapira Antony UK Novel therapies for GBA-Parkinson disease
Scheltens Philip The Netherlands The ATN Framework for AD research set to work: real world evidence
Schlossmacher Michael Canada A redox function for parkin explains its selective neuroprotection in adult human brain
Schmidt Reinhold Austria MRI as a tool to study microstructural changes in aging and dementia
Schmitz Taylor Canada In vivo molecular imaging of cortical cholinergic denervation in preclinical Alzheimer’s disease
Schneider Julie USA Neuropathologic insights into mechanisms of disease in Alzheimer’s and other Dementias
Segal Menahem Israel PRESENILIN REGULATES MITOCHONDRIAL-ER CALCIUM HOMEOSTASIS, NEURONAL PLASTICITY AND SURVIVAL OF NEURONS IN CULTURED RAT HIPPOCAMPUS: ROLE OF OXIDATIVE STRESS
Shen Jie USA APP and Presenilin in the Brain
Sisodia Sam USA Influence of the Gut Microbiome on Aβ Amyloidosis and Neuroinflammation
Snyder Peter USA Retinal Biomarkers for Pre-Clinical Alzheimer’s disease: What we know, what we don’t know, and how to move forward
Soreq Hermona Israel Investigating Alzheimer’s Disease-related roles of transfer RNA fragments in human brain nuclei
Spillantini Maria Grazia UK Investigating alpha-synuclein spreading from gut to brain
St. George-Hyslop Peter Canada Downstream TREM2 signalling in microglia
Suh Yoo Hun Korea Effects of DHED and its Derivatives, Multitarget Candidates, for the Treatment of AD
Thal Dietmar Belgium Neuropathological classification strategies in Alzheimer’s disease and its impact on clinical practice and basic research.
Thinakaran Gopal USA The functional role of the GWAS risk factor BIN1 in neurons and microglia
Trojanowski John Q. USA Multiple Proteinopathy Disorders
Van Broeckhoven Christine Belgium Rare compound coding variants might increase risk in sporadic patients with neurodegenerative brain diseases
Vassar Robert USA Aβ-accelerated neurodegeneration caused by novel Alzheimer’s-associated ACE variant R1279Q is rescued by angiotensin system inhibition
Verma Anjay USA Molecular Imaging of CNS Intrathecal Pharmacology
Villemagne Victor Australia Amyloid, tau and neuroinflammation imaging in Alzheimer’s disease
Weiner Michael USA Validating plasma tests for amyloid, tau, and neurodegeneration using the alzheimer’s disease neuroimaging initiative (adni): plasma samples are available upon request
Weiner Howard USA Immune mechanisms in Alzheimer’s disease and the role of the microbiome
Wellington Cheryl Canada The role of high density lipoproteins in the vascular contributions to Alzheimer’s Disease
Wilcock Donna USA Angiogenic dysregulation in vascular cognitive impairment and dementia
Wilson Edward United States TREM1 as a Therapeutic Target for Alzheimer’s Disease
Wong Philip USA Identification of TDP-43 cryptic exons as functional fluid biomarkers for Alzheimer’s Disease and related Dementia
Wszolek Zbigniew USA The biomarker search for SCA3
Wyss-Coray Tony USA Circulatory factors as regulators of brain aging and neurodegeneration
Xu Huaxi USA Roles for microglial Alzheimer’s risk genes in regulation of beta-amyloid metabolism and microglia function.
Zetterberg Henrik Sweden Blood biomarkers for Alzheimer’s disease and other neurodegenerative diseases – utility in clinical trials and practice
Zheng Hui USA TFEB-mediated lysosomal regulation and signaling in Alzheimer’s disease
Zhou Jiawei China Ebf1 signaling in astrocytes drives CNS inflammation
Zlokovic Berislav USA Blood-brain barrier, cognitive impairment and neurodegeneration
Bondi Mark USA Objective subtle cognitive difficulties predict amyloid accumulation and neurodegeneration
Goedert Michel UK Structures of amyloid filaments from human brain
Livesey Frederick UK Insights into pathogenesis of Alzheimer’s disease from human stem cell systems
Murray Melissa USA Selective Vulnerability of the Cholinergic Hub in the Context of Aging and Alzheimer Disease Subtypes